Search Within

Shanu Modi

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (56)
  2. Journal Article (44)
  3. Review (4)
Groups
  1. Breast Medicine Service (104)
  2. Department of Medicine (104)
  3. GSK Faculty (104)
  4. Solid Tumor Oncology Division (104)
  5. Survivorship Research (68)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (64)

More Groups

People
  1. Sarat Chandarlapaty (49)
  2. Clifford Hudis (46)
  3. Sujata Patil (32)
  4. Larry Norton (29)
  5. Komal Jhaveri (25)
  6. Chau Dang (22)

More People

Years
  1. 2024 (8)
  2. 2023 (5)
  3. 2022 (5)
  4. 2021 (6)
  5. 2020 (9)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (29)
  2. Cancer Research (24)
  3. Clinical Cancer Research (6)
  4. Breast Cancer Research and Treatment (5)
  5. Annals of Oncology (4)
  6. Clinical Breast Cancer (4)

More Publications

Publishers
  1. American Association for Cancer Research (31)
  2. American Society of Clinical Oncology (30)
  3. Nature Publishing Group (9)
  4. Elsevier Inc. (6)
  5. Oxford University Press (6)
  6. Springer (6)

More Publishers

Results (104)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i)
    Meeting Abstract

    Jhaveri, K. L.; Iyengar, N. M.; Corben, A.; Patil, S.; Akram, M.; Towers, R.; Sakr, R.; Hudis, C.; King, T. A.; Rosen, N.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
    Journal Article

    Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G.
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
    Journal Article

    Fornier, M. N.; Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Targeted therapy for human epidermal growth factor receptor 2-positive breast Cancer: Can there be too many active drugs?
    Journal Article

    Chandarlapaty, S.; Modi, S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save